Risk factors for severe COVID‐19 in hospitalized sickle cell disease patients: A study of 319 patients in France

Abstract

MultidisciplineR.pdf 4. Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.

Sickle cell disease patients with COVID‐19 in Guadeloupe: Surprisingly favorable outcomes

“…Beside obesity, SS and SC groups are remarkably similar in terms of comorbidity and vaso-occlusive events in the last 3 years. Unlike data published by Arlet et al [14] that showed in multivariate analysis that the SC genotype was a strong independent risk factor for mechanical ventilation or death, there is no difference in terms of severity and outcome of COVID-19 between SC and SS patients in our cohort. The only death occurred in an 85-year-old SC patient who had risk factors for poor prognostic.…”

“…Data on poor outcome of COVID‐19 in adults with SCD have been published through small cohorts from France, England, or America [ 13 , 14 , 15 , 16 ]. More recently, risk factors for hospitalization and serious COVID‐19 in SCD patients have been reported in 750 children and adults with SCD and COVID‐19 illness registered in the international SECURE‐SCD Registry [ 17 ].…”

COVID-19 outcomes in sickle cell disease and sickle cell trait

“…Although SCD and COVID-19 are both known to be hypercoagulable states [ [18] , [19] , [20] , [21] , [22] ], rates of venous thromboembolism were not frequently reported in studies. One study conducted in France found a high rate of pulmonary emboli among their cohort of patients with haemoglobin SC (Hb SC) disease with 25% of patients with Hb SC disease and COVID-19 diagnosed with pulmonary emboli during their hospitalization compared to 5% in the remaining population of patients with SCD and COVID-19 [ 23 ]. Another study; however, when comparing patients with SCD hospitalized for COVID-19 (281 patients) with patients with SCD not hospitalized for COVID-19 (4873 patients) found no significant difference in VTE rates within 6 months of the hospitalization, after adjusting for differences in baseline characteristics [ 24 ].…”

“…Many studies have focused on identifying potential risk factors for severe disease among patients with SCD. Arlet et al found that patients with SCD who were older than 40 years old had an 8.3-fold greater risk of intubation or death compared to patients with SCD between the ages of 20 and 40 [ 23 ]. Minniti et al also found that older age contributed to increased risk of death in patients with SCD and COVID-19 [ 12 ].…”

“…Minniti et al also replicated that serious illness secondary to COVID occurred irrespective of haemoglobin genotype [ 12 ]. Arlet et al found that after employing multivariate analysis adjusting for a number of variables including age, sex, weight, hydroxyurea use, and transfusion prior to hospitalization that Hb SC genotype was associated with a 6.99-fold increased risk for mechanical ventilation and death as compared to SS or Sβ 0 genotypes [ 23 ]. When hypothesizing what contributed to this almost 7-fold increase in intubation and death, researchers attributed a portion of the excess risk to an increased rate of venous thromboembolism and pulmonary embolism in patients with Hb SC genotype.…”